Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hopkins scientists uncover role of Fanconi’s Anemia genes in pancreatic cancer

15.05.2003


Scientists at the Johns Hopkins Kimmel Cancer Center have identified three genes, long linked to a rare inherited disease known as Fanconi’s Anemia (FA), that now appear to play a role in many cases of pancreatic cancer.



All of the genes identified, when functioning normally, are part of the DNA repair process. The work is reported in the May 15, 2003 issue of Cancer Research.

"What we think we have is a new genetic cause of some cases, approximately 10 percent or more, of pancreatic cancers, one of the most lethal forms of cancer," according to Scott Kern, M.D., professor of oncology and pathology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and director of the study. The good news is that these genes offer new targets for improved treatment, he says.


The genes have all been associated with Fanconi’s Anemia. Those affected are born with only a single normal copy of one or more of the genes. Though they do not develop FA, these people often develop pancreatic cancer, usually in their 40s and 50s, about a decade earlier than average age of onset, according to Kern.

"The up side is that while these gene mutations cause a horrific disease, they may actually be the Achilles heel of the tumor and make these particular cancers more responsive to treatment," says Kern.

The culprit genes, including BRCA2, linked by other earlier studies to breast cancer, as well as two other genes FANCC and FANCG, appear to make pancreatic cancer cells highly susceptible to treatment with two FDA-approved cancer drugs mitomycin C and cisplatin. Human clinical trials are now being planned.

Normally, the genes are responsible for keeping DNA in good repair. As DNA is copied for cell replication, these genes compare the copies of DNA and fix any breaks. Mitomycin C and cisplatin work by causing the exact breaks these genes are supposed to repair. In the subset of patients whose pancreatic cancer is caused by mutations of these repair genes, the cancer cells are missing this repair mechanism making them unable to fix the breaks caused by the drugs, so the cancer cells should die, Kern says.

Both drugs are currently used in pancreatic cancer therapy, and though some remissions have been reported, the drugs have been largely ineffective. Kern suspects it’s a matter of a patient selection and dose.

Kern says preliminary laboratory and animal studies suggest low doses over a prolonged period of time may have the most benefit, and probably only in patients with FA gene mutations. He is now working with other investigators to develop clinical trials to study the drugs in patients with early onset disease, which may be caused by FA gene mutants.

In the study, the scientists examined a panel of human pancreatic cancers. They found mutations of FA-related genes in three of nine of tumor samples from patients aged 50 or younger. The researchers believe these mutations are common among the general population, estimating that about 1 in every 300 people have inherited a mutated copy of at least one FA gene.

"Our findings also tell us that cancers that appear to occur randomly in the population may not always really be so random," Kern says. "It is likely that the origin of many cancers could be traced back to similar inherited genetic mutations," says Kern.

People born with just one normal copy of the FA genes have an unfortunate head start on the cancer process, Kern says. If that one good copy is lost from dietary and/or environmental exposures, the cellular mistakes go unchecked, accelerating the initiation of cancer. He suspects these mutations could be responsible for a subset of other cancers as well, including certain breast, ovarian, and prostate cancers.

Fanconi’s Anemia occurs in less than 1 in 100,000 people, caused by the hereditary loss of both copies of an FA gene. People with FA are born with skeletal abnormalities and often develop cancers early in life. Until now, experts did not believe the loss of only one FA gene also was disease-related. "Something we thought was not causing disease, we now suspect causes one of the worst forms of cancer," says Kern.

Pancreatic cancer has one of the lowest survival rates among all cancers. Each year, approximately 30,300 Americans are diagnosed with the disease, and nearly 30,000 die. Often unresponsive to conventional therapies, pancreatic cancer is the fourth leading cause of cancer death.

In addition to Kern, other participants in this study were Michiel S. van der Heijden, Charles J. Yeo, and Ralph H. Hruban.


This research was funded by a National Cancer Institute gastro-intestinal SPORE (Specialized Projects of Research Excellence) grant.

Valerie Matthews Mehl | EurekAlert!
Further information:
http://www.hopkinsmedicine.org
http://www.hopkinskimmelcancercenter.org

More articles from Health and Medicine:

nachricht Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin

nachricht Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

How herpesviruses win the footrace against the immune system

26.05.2017 | Life Sciences

Water forms 'spine of hydration' around DNA, group finds

26.05.2017 | Life Sciences

First Juno science results supported by University of Leicester's Jupiter 'forecast'

26.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>